Profound Medical Announces Key Presentation at Healthcare Event
Profound Medical's Upcoming Presentation Highlights
Profound Medical Corp. is set to make significant waves at an esteemed healthcare conference, aiming to showcase advancements in their innovative medical technologies. As a commercial-stage medical device company, Profound specializes in developing and marketing incision-free therapies designed to ablate diseased tissue. Their notable product offerings include the TULSA-PRO and Sonalleve systems, which are redefining treatment methodologies.
Showcasing Innovation at the Conference
During the 43rd Annual J.P. Morgan Healthcare Conference, management will deliver a comprehensive update on their business progress and cutting-edge technology. The event is an invaluable platform for Profound Medical (NASDAQ:PROF; TSX:PRN) to connect with industry leaders, investors, and peers in the medical community. Those unable to attend can view the presentation live on the company’s official website, ensuring accessibility for all stakeholders.
Understanding the TULSA-PRO Technology
The TULSA-PRO system represents a pioneering step in prostate treatment. This advanced device leverages real-time MRI guidance combined with robotically-driven transurethral ultrasound, providing precision in targeting prostate tissue. The procedure is designed to be both effective and patient-friendly, helping to preserve essential functions while effectively treating conditions like prostate cancer and benign prostatic hyperplasia (BPH).
The Advantages of TULSA-PRO
TULSA-PRO offers a “one-and-done” procedure, allowing patients to receive treatment in a single session that lasts just a few hours. Importantly, there's no need for incisions, which eliminates risks associated with traditional surgical approaches such as bleeding or prolonged recovery times. Most patients experience a swift return to normal activities, making this technology a compelling choice for many.
Exploring the Sonalleve Platform
In addition to TULSA-PRO, Profound Medical is also focused on the Sonalleve platform. This innovative therapy is tailored for treating uterine fibroids and managing palliative pain associated with bone metastases. The technology is currently CE marked and has received approval for use in various international markets, including the U.S. under a Humanitarian Device Exemption.
Potential Applications of Sonalleve
Profound is actively exploring further applications for Sonalleve, aiming to expand its reach in the medical community. Current research and clinical applications may include non-invasive treatments for abdominal cancers, showcasing the versatility and potential of this technology across multiple medical fields.
Company Overview and Future Directions
As a leader in the medical device sector, Profound Medical is committed to advancing patient care through innovative solutions. Their products have already demonstrated significant capacities in addressing complex medical conditions, aiming to improve patient outcomes substantially. With rigorous regulatory approvals across their technology platforms, Profound continues to focus on developing therapies that can provide relief to patients around the globe.
Connect with Profound Medical
For further inquiries about Profound Medical’s initiatives, investors are encouraged to reach out to their Investor Relations team. Stephen Kilmer, the point of contact, is available via email for detailed questions, while Susan Thomas manages public relations and outreach efforts.
Frequently Asked Questions
What is the primary focus of Profound Medical Corp.?
Profound Medical focuses on developing incision-free therapies for the treatment of diseased tissue, specifically targeting prostate-related health issues and conditions like uterine fibroids.
When and where will the company present at the healthcare conference?
Profound Medical will present at the 43rd Annual J.P. Morgan Healthcare Conference on a scheduled date, highlighting their innovative technologies.
What are the benefits of the TULSA-PRO procedure?
The TULSA-PRO procedure is minimally invasive, allows for quick recovery, and effectively treats various prostate conditions without the need for hospitalization.
How is Sonalleve different from TULSA-PRO?
Sonalleve is designed primarily for the treatment of uterine fibroids and managing palliative pain, while TULSA-PRO targets prostate health, showcasing the diversity in treatment options provided by Profound Medical.
How can I learn more about Profound Medical’s technologies?
You can visit Profound Medical's website, where they provide detailed information about their technologies, ongoing clinical research, and contact details for further inquiries.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. If any of the material offered here is inaccurate, please contact us for corrections.
